Eli Lilly and Co
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 800
- Registration Number
- NCT06662383
- Locations
- ๐บ๐ธ
Medical Advancement Centers of Arizona, Tempe, Arizona, United States
๐บ๐ธMary & Dick Allen Diabetes Center, Newport Beach, California, United States
๐บ๐ธArtemis Institute for Clinical Research, San Diego, California, United States
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT06657768
- Locations
- ๐บ๐ธ
Collaborative Neuroscience Network - CNS, Los Alamitos, California, United States
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1200
- Registration Number
- NCT06653153
- Locations
- ๐บ๐ธ
Parkway Medical Center, Birmingham, Alabama, United States
๐บ๐ธMD First Research - Chandler, Chandler, Arizona, United States
๐บ๐ธHealthy Brain Clinic, Long Beach, California, United States
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT06649045
- Locations
- ๐บ๐ธ
Ark Clinical Research, Long Beach, California, United States
๐บ๐ธPeninsula Research Associates, Rolling Hills Estates, California, United States
๐บ๐ธArtemis Institute for Clinical Research, San Diego, California, United States
A Study of [14C]-LY3866288 in Healthy Participants
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06644378
- Locations
- ๐บ๐ธ
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT06643728
- Locations
- ๐บ๐ธ
Eastside Research Associates, Redmond, Washington, United States
๐บ๐ธPinnacle Research Group, LLC, Anniston, Alabama, United States
๐บ๐ธCentral Research Associates, Birmingham, Alabama, United States
A Study of LY3866288 in Healthy Participants
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT06641037
- Locations
- ๐บ๐ธ
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 180
- Registration Number
- NCT06635057
- Locations
- ๐ธ๐ฆ
Al Moosa Hospital, Al Mubarraz, Al-Ahsa, Saudi Arabia
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT06607185
- Locations
- ๐จ๐ณ
Hsin-Chu Hospital, Hsin-chu, Taiwan
๐จ๐ณNational Taiwan University Hospital, Taipei, Taiwan
๐บ๐ธSTART Midwest, Grand Rapids, Michigan, United States
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 230
- Registration Number
- NCT06606106
- Locations
- ๐บ๐ธ
Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States
๐บ๐ธFortrea Clinical Research Unit, Dallas, Texas, United States
๐บ๐ธClinical Pharmacology of Miami, Miami, Florida, United States